Print Page | Close Page

 
 

HanchorBio

Address: Taipei,
 
Country: Taiwan
 
Sectors: Collaborations & Partnerships- R&D, Collaborations & Partnerships-Licensing, Proprietary Research & Manufacture
 
Website: https://www.hanchorbio.com/en/contact/
 
- - -
 

About Us

HanchorBio (漢康生技) is developing a technology for the creation of next generation personalized biotherapeutics. Based in San Francisco, Taipei, and Shanghai, we are led by a group of pharmaceutical industry veterans with proven track-record of success is biologics discovery and global development with bold vision to rewrite immunotherapies. Committed to reactivating the immune system to fight against diseases, our proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to help revolutionize the treatment of people with cancer and other debilitating diseases. Our FBDB™ platform has successfully delivered proof-of-concept data in several in-vivo animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing methodology in CMC, we develop transformative medicines to address unmet medical needs.

 
- - -
 

Sectors

  • Collaborations & Partnerships- R&D
  • Collaborations & Partnerships-Licensing
 
  • Proprietary Research & Manufacture
 
- - -
 

Categories

  • Biologics
  • Immunotherapy
  • Oncology Products
  • immuno-oncology
  • Autoimmune Products
 
  • Proteins
  • Antibodies-Fusion
  • Tumour Targeting
  • Clinical Development-Pipeline
 
- - -
 

News

 
27th January 2026
 

HanchorBio and WuXi Biologics Enter Strategic Partnership

 

 HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

 
- - -
 
Printed: 15-Mar-2026 at 09:08:30 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com